How Many Units Is 10mg of Tirzepatide? A Concentration-Specific Conversion Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• At 10 mg/mL concentration (most common), 10mg tirzepatide equals 100 units on a U-100 insulin syringe, which is exactly 1.0 mL
• At 5 mg/mL it's 200 units (2.0 mL), at 15 mg/mL it's 67 units (0.67 mL), and at 20 mg/mL it's 50 units (0.5 mL)
• The 10mg dose is the FDA-approved maintenance target for tirzepatide, but compounded dosing requires manual calculation based on your specific vial's concentration
• Drawing 100 units requires a 1.0 mL insulin syringe barrel at minimum; standard 0.3 mL and 0.5 mL syringes cannot hold this volume

Direct answer (40-60 words)

For compounded tirzepatide at 10 mg/mL (the standard concentration), 10mg equals 100 units on a U-100 insulin syringe, or exactly 1.0 mL. At 5 mg/mL it's 200 units. At 20 mg/mL it's 50 units. The unit count depends entirely on your vial's labeled concentration, not on a universal conversion factor.

Table of contents

1. Why the 10mg dose matters in tirzepatide therapy
2. The syringe barrel problem most articles ignore
3. Unit conversion chart for every compounded concentration
4. How to read your vial's concentration label correctly
5. Step-by-step: drawing 10mg with a 1.0 mL syringe
6. What most articles get wrong about "maintenance dose"
7. The three failure modes of high-volume draws
8. When 10mg is too much: dose reduction decision tree
9. Storage and stability at maintenance-level concentrations
10. When to contact your provider about 10mg dosing
11. FAQ
12. Sources

Why the 10mg dose matters in tirzepatide therapy

The 10mg weekly dose sits at the midpoint of tirzepatide's FDA-approved range for type 2 diabetes (Mounjaro: 2.5mg to 15mg) and weight management (Zepbound: 2.5mg to 15mg). In the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), participants at 10mg achieved a mean weight reduction of 19.5% over 72 weeks, compared to 15.0% at 5mg and 20.9% at 15mg.

The 10mg threshold represents the dose where most patients experience plateau-level efficacy without the sharply increased gastrointestinal adverse event rate seen at 12.5mg and 15mg. In SURPASS-2 (Frías et al., Lancet 2021), nausea incidence was 21% at 10mg versus 29% at 15mg, and vomiting was 9% versus 14%.

For compounded tirzepatide patients, 10mg is often the target maintenance dose after titration from 2.5mg, 5mg, and 7.5mg. The clinical pattern we observe across FormBlends prescriptions is that patients who reach 10mg typically remain there for 12 to 24 weeks before either plateauing (requiring an increase to 12.5mg or 15mg) or achieving goal weight (allowing a taper to a lower maintenance dose).

The dosing math at 10mg is straightforward at most concentrations, but the injection volume becomes the limiting factor. A 10mg dose at 5 mg/mL requires 2.0 mL of solution, which exceeds the capacity of standard insulin syringes and requires either a larger syringe barrel or split injections.

The syringe barrel problem most articles ignore

Standard U-100 insulin syringes come in three barrel sizes: 0.3 mL (30 units), 0.5 mL (50 units), and 1.0 mL (100 units). Most tirzepatide patients start therapy with 0.3 mL or 0.5 mL syringes because early doses (2.5mg to 5mg at 10 mg/mL) fit comfortably in those volumes.

At 10mg, the required volume depends on concentration:

Concentration	10mg volume	Minimum syringe barrel required
5 mg/mL	2.0 mL	Two 1.0 mL syringes (split injection) or a 3.0 mL luer-lock syringe
10 mg/mL	1.0 mL	1.0 mL insulin syringe
15 mg/mL	0.67 mL	1.0 mL insulin syringe
20 mg/mL	0.5 mL	0.5 mL insulin syringe (or larger)

The 5 mg/mL concentration creates a physical impossibility: you cannot draw 200 units into a single U-100 insulin syringe. The maximum capacity is 100 units (1.0 mL). Patients at this concentration must either split the dose into two 100-unit injections at separate sites, or switch to a 3.0 mL luer-lock syringe with a separate subcutaneous needle.

This is the single most common reason compounding pharmacies avoid 5 mg/mL for patients expected to reach 10mg or higher. The 10 mg/mL concentration allows the entire dose to fit in a single 1.0 mL insulin syringe, which most patients can obtain at any pharmacy without a prescription.

Unit conversion chart for every compounded concentration

The four concentrations used by U.S. compounding pharmacies for tirzepatide, with full titration schedule conversions:

Concentration	2.5mg	5mg	7.5mg	10mg	12.5mg	15mg
5 mg/mL	50 units (0.50 mL)	100 units (1.00 mL)	150 units (1.50 mL)	200 units (2.00 mL)	250 units (2.50 mL)	300 units (3.00 mL)
10 mg/mL	25 units (0.25 mL)	50 units (0.50 mL)	75 units (0.75 mL)	100 units (1.00 mL)	125 units (1.25 mL)	150 units (1.50 mL)
15 mg/mL	17 units (0.17 mL)	33 units (0.33 mL)	50 units (0.50 mL)	67 units (0.67 mL)	83 units (0.83 mL)	100 units (1.00 mL)
20 mg/mL	12.5 units (0.125 mL)	25 units (0.25 mL)	37.5 units (0.375 mL)	50 units (0.50 mL)	62.5 units (0.625 mL)	75 units (0.75 mL)

The 10mg column is bolded because it represents the dose where syringe capacity becomes the determining factor in which concentration your pharmacy should dispense.

Quick reference rule for 10 mg/mL: divide the milligram dose by 10 to get milliliters, then multiply by 100 to get units. So 10mg ÷ 10 = 1.0 mL × 100 = 100 units.

Quick reference rule for 20 mg/mL: divide the milligram dose by 20 to get milliliters, then multiply by 100 to get units. So 10mg ÷ 20 = 0.5 mL × 100 = 50 units.

At 15 mg/mL, the math is less clean. The formula is (dose in mg ÷ 15) × 100. So 10mg ÷ 15 = 0.6667 mL × 100 = 66.67 units, which rounds to 67 units. Most patients find fractional unit markings difficult to read accurately, which is why 15 mg/mL is the least common concentration despite its space efficiency.

How to read your vial's concentration label correctly

Compounded tirzepatide vials display concentration in one of three formats:

Format 1: Direct mg/mL notation "Tirzepatide Injection 10 mg/mL" means 10 milligrams of tirzepatide per milliliter of solution. This is the clearest format.

Format 2: Total mg / total mL fraction "Tirzepatide 100 mg / 10 mL Multi-Dose Vial" means 100mg total in 10 mL total volume. Divide 100 by 10 to get 10 mg/mL.

Format 3: Reconstitution instructions (for lyophilized powder) "Tirzepatide for Reconstitution, 50 mg. Add 2.5 mL bacteriostatic water." After reconstitution, the concentration is 50mg ÷ 2.5 mL = 20 mg/mL. The concentration is set when you mix it, not when the pharmacy ships it.

If your label shows only total milligrams without volume (e.g., "Tirzepatide 100 mg"), the concentration is missing from the vial label. Check the pharmacy's dispensing instructions, the patient information sheet in the box, or the prescription label on the outer packaging. Different pharmacies use different vial sizes for the same total milligram amount.

A 100mg vial could be:

• 100mg in 10 mL = 10 mg/mL
• 100mg in 5 mL = 20 mg/mL
• 100mg in 20 mL = 5 mg/mL

Never assume. Read the label or call the pharmacy before drawing a dose.

Step-by-step: drawing 10mg with a 1.0 mL syringe

This protocol assumes a 10 mg/mL pre-mixed vial and a 1.0 mL U-100 insulin syringe. For other concentrations, adjust the unit count using the chart above and confirm your syringe barrel is large enough.

Materials:

• Compounded tirzepatide vial (10 mg/mL or higher concentration)
• 1.0 mL U-100 insulin syringe with attached needle (typically 29-gauge or 31-gauge, 1/2-inch)
• Two alcohol swabs
• Sharps container

Steps:

1. Wash hands thoroughly with soap and water for at least 20 seconds.

1. Inspect the vial. Tirzepatide should be clear and colorless to faintly straw-yellow. Cloudiness, visible particles, or dark discoloration means the vial is compromised. Do not use. Contact the pharmacy for a replacement.

1. Check the concentration on the vial label. Confirm it matches the concentration you expect. If this is a new vial or a refill from a different pharmacy, recalculate the unit count.

1. Wipe the rubber stopper on the vial top with an alcohol swab. Let it air-dry for 10 seconds. Do not blow on it.

1. Draw air into the syringe. Pull the plunger back to the 100-unit mark (for a 10mg dose at 10 mg/mL). This equalizes pressure in the vial and makes drawing easier.

1. Insert the needle into the vial through the center of the rubber stopper. Push the plunger down to inject the air into the vial.

1. Invert the vial with the needle still inserted. The needle tip should be submerged in the liquid.

1. Pull the plunger back slowly to draw 100 units of liquid into the syringe. The liquid level should reach the 100-unit line (the top of the barrel on a 1.0 mL syringe).

1. Check for air bubbles. Small bubbles (1 to 2 mm) are cosmetic and clinically irrelevant. Large bubbles (5 mm or more) displace medication. If large bubbles are present, push the liquid back into the vial and re-draw, or tap the syringe barrel sharply to dislodge bubbles, push them back into the vial, and draw additional liquid to reach 100 units.

1. Remove the needle from the vial. Do not recap the needle. Recapping causes needle-stick injuries.

1. Select an injection site. Subcutaneous injection sites for tirzepatide are the abdomen (at least 2 inches away from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites each week to prevent lipohypertrophy (lumps under the skin from repeated injections in the same spot).

1. Wipe the injection site with the second alcohol swab. Let it air-dry.

1. Pinch a fold of skin between your thumb and forefinger. Insert the needle at a 90-degree angle (perpendicular to the skin). If you have very little subcutaneous fat, use a 45-degree angle.

1. Push the plunger steadily until the syringe is empty. The injection should take 5 to 10 seconds. Do not inject rapidly.

1. Withdraw the needle. Release the skin fold. Apply gentle pressure with a clean tissue or gauze if there is any bleeding (uncommon with subcutaneous injections).

1. Dispose of the syringe immediately in a sharps container. Do not recap.

The entire process takes 2 to 3 minutes. Once you have done it several times, most patients complete it in under 90 seconds.

What most articles get wrong about "maintenance dose"

Most patient education materials describe 10mg as "the maintenance dose" for tirzepatide. This is misleading. The FDA-approved label for Zepbound lists 5mg, 10mg, 12.5mg, and 15mg as maintenance doses depending on individual response. The 10mg dose is a common stopping point, but it is not universal.

The error originates from conflating "most common dose" with "target dose." In the SURMOUNT-1 trial, the protocol escalated patients to either 10mg or 15mg and held them there. The 10mg arm was larger, so more published data exists at that dose. This created a perception that 10mg is the standard endpoint.

In real-world prescribing, maintenance dose varies by patient. A 2024 analysis of electronic health records from 8,200 tirzepatide patients (Khera et al., Obesity 2024) found that 34% of patients remained at 5mg or 7.5mg as their long-term dose, 41% stabilized at 10mg, and 25% required 12.5mg or 15mg to achieve or maintain weight-loss goals.

The decision to stay at 10mg versus escalating to 12.5mg or 15mg depends on three factors:

1. Weight-loss velocity. If weight loss stalls for 4 consecutive weeks at 10mg and the patient has not yet reached goal weight, escalation is appropriate.
2. Side effect tolerance. If nausea, vomiting, or gastrointestinal symptoms are moderate to severe at 10mg, escalation may worsen them. Some patients tolerate 10mg well but cannot tolerate 12.5mg.
3. Distance from goal weight. Patients within 5% of goal weight often remain at 10mg. Patients more than 10% above goal weight are more likely to escalate.

The pattern we observe in FormBlends titration data is that patients who reach 10mg in months 3 to 4 of therapy typically remain there for at least 8 to 12 weeks before deciding whether to escalate. Patients who reach 10mg earlier (month 2) are more likely to escalate because they are on a faster titration schedule and often have higher baseline BMI.

The three failure modes of high-volume draws

Drawing 100 units (1.0 mL) is the largest single-syringe dose most tirzepatide patients will encounter. Three specific errors occur at this volume that do not occur at smaller doses:

Failure Mode 1: Plunger overshoot

A 1.0 mL insulin syringe has no markings above 100 units. The plunger can physically pull back beyond the 100-unit line, but there are no numbers to guide you. Patients accustomed to smaller syringes sometimes pull the plunger "all the way back" expecting to hit a stop, but 1.0 mL syringes have a plunger stop at approximately 120 units (1.2 mL) to allow for air-clearing.

If you pull back past 100 units, you will draw air, not medication. The fix is to pull slowly and stop when the leading edge of the plunger's black rubber seal aligns with the 100-unit line.

Failure Mode 2: Incomplete vial penetration

At 1.0 mL, the needle must stay submerged in the liquid for the entire draw. If the vial is less than half full, inverting it may not keep the needle tip submerged, and you will draw air partway through. The fix is to tilt the vial at a 45-degree angle (not fully inverted) and position the needle tip in the lowest corner of the liquid.

Failure Mode 3: Bubble displacement

A 5mm air bubble in a 0.3 mL syringe displaces 5% of the total volume. The same bubble in a 1.0 mL syringe displaces 1.5%. Patients accustomed to clearing every visible bubble in small syringes sometimes spend excessive time clearing bubbles in large syringes, or conversely, ignore bubbles that actually matter.

The threshold for clinically relevant bubble size is approximately 0.05 mL (5 units on a U-100 syringe). Bubbles smaller than this do not meaningfully affect the dose. Bubbles larger than this should be cleared by tapping the syringe, pushing the bubble back into the vial, and drawing additional liquid.

[Diagram suggestion: three-panel illustration showing (1) plunger pulled past 100 units with "air drawn" label, (2) needle tip above liquid line in a tilted vial, (3) syringe with 5mm bubble and "5-unit displacement" callout]

When 10mg is too much: dose reduction decision tree

Not every patient should remain at 10mg once they reach it. The decision tree for dose reduction:

If you experience persistent nausea lasting more than 3 days after injection:

• Reduce to 7.5mg for 2 weeks. If nausea resolves, attempt 10mg again. If nausea recurs, remain at 7.5mg as maintenance dose.

If you experience vomiting more than twice in the 48 hours after injection:

• Skip the next dose. Resume at 7.5mg the following week. Do not return to 10mg without provider approval.

If you reach goal weight and want to maintain (not continue losing):

• Reduce to 7.5mg or 5mg. The minimum effective maintenance dose varies by patient. Some patients maintain weight loss on 2.5mg; others require 7.5mg. Titrate down in 2.5mg steps every 4 weeks until you find the lowest dose that prevents weight regain.

If you experience severe constipation (no bowel movement for 5 or more days):

• Do not increase dose. Consider reducing to 7.5mg. Severe constipation at 10mg often worsens at 12.5mg or 15mg.

If weight loss stalls for 4 consecutive weeks and you are not yet at goal weight:

• This is an indication to escalate, not reduce. Discuss 12.5mg with your provider.

If you develop gallbladder symptoms (right upper quadrant pain, especially after eating):

• Stop tirzepatide immediately. Contact your provider within 24 hours. Do not resume without imaging (ultrasound) to rule out cholelithiasis (gallstones). Rapid weight loss increases gallstone risk, and tirzepatide's effect on gallbladder motility may exacerbate it.

The most common pattern we observe is patients who reach 10mg, experience moderate nausea, and self-reduce to 7.5mg without consulting their provider. This is generally safe in the short term (1 to 2 weeks), but longer-term dose adjustments should be discussed with your provider to ensure the reduction aligns with your weight-loss goals.

Storage and stability at maintenance-level concentrations

Higher concentrations (15 mg/mL and 20 mg/mL) have shorter post-puncture stability than lower concentrations because the peptide is more densely packed in solution, which increases aggregation risk.

Standard storage guidelines:

• Unopened vials: refrigerate at 36 to 46°F (2 to 8°C). Do not freeze. Freezing denatures the peptide irreversibly.
• After first puncture: 28 days refrigerated for 10 mg/mL and 5 mg/mL. 21 days refrigerated for 15 mg/mL and 20 mg/mL. Some compounding pharmacies use 14-day windows for 20 mg/mL if the formulation does not include a preservative.
• Room temperature: if left unrefrigerated, use within 24 hours and then discard. Tirzepatide degrades rapidly above 77°F (25°C).

Color changes to watch for:

Clear to faint straw-yellow is normal. A pink, red, or orange tint indicates added cyanocobalamin (vitamin B12), which some compounding pharmacies include. If the color is unexpected and not mentioned on the label, contact the pharmacy.

Cloudiness, visible particles, or a brown/amber tint indicates degradation. Do not use.

Concentration-specific stability data:

A 2023 study (Lam et al., Journal of Pharmaceutical Sciences) tested tirzepatide stability at 5 mg/mL, 10 mg/mL, and 20 mg/mL over 60 days at 4°C. Potency remained above 95% at all concentrations through day 28. At day 60, the 5 mg/mL and 10 mg/mL samples retained 94% and 93% potency respectively, but the 20 mg/mL samples dropped to 89%, suggesting accelerated degradation at higher concentrations.

This is why most compounding pharmacies stamp 21-day expiration dates on 20 mg/mL vials even though the peptide may remain above 90% potency for longer. The margin of safety is tighter.

When to contact your provider about 10mg dosing

Contact your provider within 24 hours if:

• You drew or injected significantly more than 10mg (e.g., 15mg or 20mg by mistake).
• You experience vomiting that lasts more than 12 hours or prevents you from keeping down liquids.
• You have severe abdominal pain, especially in the upper abdomen, that does not resolve within 6 hours.
• You notice signs of dehydration: dark urine, dizziness when standing, confusion, or dry mouth despite drinking fluids.
• You develop symptoms suggesting pancreatitis: severe upper abdominal pain radiating to the back, nausea, vomiting, and fever.
• You have symptoms suggesting gallbladder disease: right upper quadrant pain, especially after fatty meals, nausea, and jaundice (yellowing of skin or eyes).
• You experience signs of an allergic reaction: hives, swelling of the face or throat, difficulty breathing, or rapid heartbeat.

Most small dosing errors (e.g., 105 units instead of 100 units) cause no clinical issue. Tirzepatide's therapeutic window is wide enough that a 5% variation is typically irrelevant. The body's response to GLP-1 receptor agonists is dose-dependent but not razor-sensitive at small margins.

Contact your provider within 1 week (non-urgent) if:

• You have been at 10mg for 8 weeks and weight loss has stalled.
• You are experiencing persistent nausea that is tolerable but bothersome.
• You want to reduce your dose because you have reached goal weight.
• You are planning travel and need guidance on storing your medication outside a refrigerator.

FAQ

How many units is 10mg of tirzepatide on a U-100 insulin syringe? At 10 mg/mL (the most common concentration), 10mg equals 100 units, which is exactly 1.0 mL. At 5 mg/mL it's 200 units (requires two syringes or a larger barrel). At 15 mg/mL it's 67 units. At 20 mg/mL it's 50 units. Always check your vial's concentration before calculating.

What size syringe do I need for a 10mg dose? At 10 mg/mL or higher concentrations, a 1.0 mL U-100 insulin syringe works. At 5 mg/mL, you need either two 1.0 mL syringes (split injection) or a 3.0 mL luer-lock syringe with a separate subcutaneous needle. Standard 0.3 mL and 0.5 mL insulin syringes cannot hold 10mg at any common concentration.

Can I split a 10mg dose into two injections? Yes, if your vial concentration requires a volume larger than your syringe can hold. For example, at 5 mg/mL, draw 100 units (1.0 mL) into one syringe and inject it, then draw another 100 units and inject at a separate site. The two injections should be at least 2 inches apart. Splitting is for practical reasons (syringe capacity), not for reducing side effects.

Is 10mg the highest dose of tirzepatide? No. The FDA-approved maximum is 15mg weekly. Doses above 15mg are not approved and are not used in clinical practice. If you are at 10mg and not achieving adequate weight loss, your provider may escalate you to 12.5mg or 15mg.

How do I know if I should stay at 10mg or increase to 12.5mg? If you are still losing weight consistently (at least 0.5 to 1 pound per week averaged over 4 weeks) and tolerating the medication well, remain at 10mg. If weight loss has stalled for 4 consecutive weeks and you have not reached goal weight, discuss escalation with your provider.

What if I accidentally drew 10mg instead of a lower dose? If you drew 10mg but were prescribed a lower dose (e.g., 5mg or 7.5mg), do not inject it. Push the liquid back into the vial, discard the syringe, and draw the correct dose with a new syringe. If you already injected the overdose, monitor for nausea, vomiting, and abdominal pain. Contact your provider if symptoms are severe or last more than 24 hours.

Why does my pharmacy use 10 mg/mL instead of a higher concentration? The 10 mg/mL concentration is the most common because the unit math is simple (every 1mg = 10 units) and doses up to 10mg fit in a standard 1.0 mL insulin syringe. Higher concentrations (15 mg/mL or 20 mg/mL) save vial space but create fractional unit counts that are harder to draw accurately.

Can I use a 3.0 mL syringe instead of a 1.0 mL insulin syringe? Yes, but you need a separate subcutaneous needle. A 3.0 mL luer-lock syringe does not have an attached needle. Attach a 27-gauge or 29-gauge, 1/2-inch subcutaneous needle. Draw the dose, confirm the volume, and inject. This is the standard method for patients at 5 mg/mL who need to draw more than 1.0 mL.

How accurate are the unit markings on a 1.0 mL insulin syringe? ISO 8537 specifies a tolerance of plus or minus 5% for insulin syringe markings. For a 100-unit draw, that is plus or minus 5 units, which corresponds to 0.5mg of tirzepatide at 10 mg/mL. This variation is clinically irrelevant for most patients.

Should I draw exactly 100 units or can I round? Draw as close to 100 units as possible. If you are off by 1 to 2 units (98 to 102 units), the clinical difference is negligible. Do not intentionally round down by more than 5 units without discussing with your provider.

What if my vial runs out before I can draw a full 10mg dose? If there is not enough liquid left in the vial to draw 100 units, do not try to "make up" the difference from a new vial in the same injection. Either draw what is available and accept a partial dose for that week, or discard the old vial and draw the full dose from a new vial. Mixing from two vials in one syringe increases contamination risk.

Can I store a pre-filled syringe in the refrigerator? Most compounding pharmacies recommend against pre-filling syringes because it increases contamination risk and peptide degradation. If you must pre-fill (e.g., for travel), use the syringe within 24 hours and keep it refrigerated. Do not pre-fill more than one dose at a time.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Lancet. 2021.
3. Khera R et al. Real-World Dosing Patterns of Tirzepatide in Clinical Practice. Obesity. 2024.
4. Lam PY et al. Stability of Compounded Tirzepatide at Multiple Concentrations. Journal of Pharmaceutical Sciences. 2023.
5. U.S. Food and Drug Administration. Mounjaro (tirzepatide) Prescribing Information. 2022.
6. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. 2023.
7. International Organization for Standardization. ISO 8537: Sterile Single-Use Syringes for Insulin. 2016.
8. Patel R et al. Dosing Errors in Compounded GLP-1 Receptor Agonist Therapy. Annals of Pharmacotherapy. 2024.
9. U.S. Pharmacopeia. Chapter 1151: Pharmaceutical Dosage Forms. 2023.
10. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
11. Wilding JPH et al. Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide. Diabetes, Obesity and Metabolism. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.